Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Permethrin + ivermectin is a combination therapy consisting of topical permethrin (usually 5% cream) and oral ivermectin, used primarily for the treatment of scabies, especially severe or crusted (Norwegian) scabies. Permethrin is a synthetic pyrethroid that acts as a neurotoxin to mites by disrupting sodium channel function in nerve cell membranes, leading to paralysis and death of the parasite. Ivermectin is an oral antiparasitic agent that binds selectively to glutamate-gated chloride ion channels in nerve and muscle cells of parasites, causing hyperpolarization, paralysis, and death. The combination approach leverages both topical and systemic mechanisms to increase efficacy—particularly important in cases where monotherapy may be insufficient due to high mite burden or compromised skin integrity[2][3][5][7]. Clinical studies indicate that this combination can achieve higher cure rates than either agent alone for severe forms of scabies[2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on permethrin + ivermectin.